leon-nanodrugs GmbH
LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles
EQS-News: leon-nanodrugs GmbH
/ Key word(s): Research Update
LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles
January 3, 2023 – Munich (Germany) – leon-nanodrugs GmbH (“LEON”), a disrupting enabler of nanotechnology for the pharmaceutical industry, today announces the successful completion of its reactor development. With all prerequisites set for serial production, the proprietary reactor will now provide excellent inter-device reproducibility of nanoparticle features. This is a technological breakthrough for production of LNPs, as well as for encapsulation of transfection material (such as mRNA) or active pharmaceutical ingredients (APIs), at any stage of preclinical and clinical development up to market supply. Christian Nafe, CFO of LEON, commented: “The results of our reactor studies strongly support that LEON has reached an important milestone in product development and is well on its way towards commercialization. Our reactor is manufactured by Harro Höfliger with highest precision. This enables us to deliver on our promise of seamless process transfer – from preclinical scale for product and process development up to market supply. The implementation of the reactor in all devices of our NANOnow platform puts us on the right track to bring our solution for a significantly faster and more efficient production of LNPs and other gene transfer products to the market and to meet the requirements of the biopharmaceutical industry.” “Our proprietary reactor can now be manufactured with high precision, leading to an exceptionally low variability. The modular system has interchangeable nozzles with a diameter between 100 µm and 500 µm with a deviation of only 2 µm. Consequently, we can measure excellent data in terms of particle size reproducibility and distribution,” added Dr. Frank Stieneker, CSO of LEON. “These great results would not have been possible without the dedicated and passionate work of our research team, for which I am truly thankful.”
– – – – – leon-nanodrugs’ (“LEON”) aim is to create a new norm for the production of nanoparticle-based therapeutics by establishing their technology for seamless scale-up and high-performance output. The Munich-based private company was founded in 2011 and since then has successfully pursued its mission of enabling the biotechnology and pharmaceutical industry, as well as Contract Development and Manufacturing Organizations (CDMOs), with a disruptive manufacturing technology to encapsulate mRNAs or active pharmaceutical ingredients (APIs) into lipid nanoparticles (LNPs). The increase in efficiency and speed will broaden access to mRNA vaccines, therapeutically enhanced biologics or small molecules, and improve economic feasibility for the benefit of patients and healthcare systems. LEON’s intellectual property is broadly protected with international coverage through 2041. For further information, please visit https://leon-nanodrugs.com/ and follow us on LinkedIn and Twitter.
03.01.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. |
Language: | English |
Company: | leon-nanodrugs GmbH |
Kopernikusstraße 9 | |
81679 Munich | |
Germany | |
E-mail: | info@leon-nanodrugs.com |
Internet: | https://leon-nanodrugs.com/ |
EQS News ID: | 1526127 |
End of News | EQS News Service |